News Perlmutter's Eikon raises $351m in major financing round Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.
News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News Ascentage raises $126m in first biotech IPO of 2025 China's Ascentage completes the first US biotech IPO of 2025, raising $126m for its pipeline of small-molecule cancer drugs.
News AMR biotech BioVersys plans to float on Swiss stock exchange BioVersys has filed to list on the Swiss Stock Exchange, hoping to raise CHF80m for its novel antibacterial candidates.
News Two more biotechs join IPO waiting list Odyssey and Sionna have filed to carry out IPOs on the Nasdaq, following after Metsera and Maze which filed earlier in January.
News Kardigan raises $300m for cardio work, and other financings Kardigan makes its debut with a teal of ex-MyoKardia execs and a $300m war chest, with a string of other biotechs also raising funds this week.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
